Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies
Other
Lachowiez CA. et al, (2024)
Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies
Other
Lachowiez CA. et al, (2024)
Genome-wide association studies of Down syndrome associated congenital heart defects
Preprint
Feldman ER. et al, (2024)
Risk Stratification in Older Intensively Treated Patients With AML.
Journal article
Versluis J. et al, (2024), J Clin Oncol
Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.
Journal article
Aksöz M. et al, (2024), Sci Immunol, 9
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Journal article
Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17
Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.
Journal article
Cogswell TJ. et al, (2024), RSC Med Chem
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Journal article
Risueño A. et al, (2024), Leukemia Research, 140
HDAC inhibitor derivatives induce differentiation of leukemic cells through two distinct and separable mechanisms
Preprint
Kumar P. et al, (2024)
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Journal article
Rajakumaraswamy N. et al, (2023), Clin Lymphoma Myeloma Leuk
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Journal article
Freeman SD. et al, (2023), Blood, 142, 1697 - 1707
Changing treatment changing prognosis of mutations
Journal article
Vyas P., (2023), Blood, 142, 1583 - 1585
A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.
Journal article
Turkalj S. et al, (2023), STAR Protoc, 4
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Preprint
Jakobsen NA. et al, (2023)
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
Journal article
Daver NG. et al, (2023), J Clin Oncol
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Journal article
Lachowiez CA. et al, (2023), Blood Cancer Discov, 4, 276 - 293
Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Other
Lachowiez CA. et al, (2023)
Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Dataset
Lachowiez CA. et al, (2023)